LEADER 03145nam 2200649Ia 450 001 9910454146903321 005 20200520144314.0 010 $a1-281-80665-X 010 $a9786611806651 010 $a0-8261-1534-9 035 $a(CKB)1000000000704997 035 $a(EBL)423414 035 $a(OCoLC)476262739 035 $a(SSID)ssj0000141551 035 $a(PQKBManifestationID)11151387 035 $a(PQKBTitleCode)TC0000141551 035 $a(PQKBWorkID)10090932 035 $a(PQKB)10130048 035 $a(MiAaPQ)EBC423414 035 $a(Au-PeEL)EBL423414 035 $a(CaPaEBR)ebr10265604 035 $a(CaONFJC)MIL180665 035 $a(EXLCZ)991000000000704997 100 $a20010918d2002 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aDrug discovery and development for Alzheimer's disease 2000$b[electronic resource] /$fHoward M. Fillit, Alan W. O'Connell, editors 210 $aNew York $cSpringer Pub Co.$dc2002 215 $a1 online resource (297 p.) 225 1 $aISOA Annual Investigators Meeting 300 $a"Papers presented at a meeting held at Tarrytown House, NY, on October 29-31, 2000, the first in a planned series entitled, "Advances in Drug Discovery and Drug Development for Cognitive Aging and Alzheimer's Disease"-- P. 3-4 of introd. 311 $a0-8261-1542-X 320 $aIncludes bibliographical references and index. 327 $aContents; Contributors; Acknowledgments; 1 The Challenges of Drug Discovery and Drug Development for Cognitive Aging and Alzheimer's Disease; Part I. Early Detection; Part II. Drug Discovery; Part III. Drug Development-Preclinical; Part IV. Drug Development-Clinical; Index 330 $aThis prestigious volume presents the findings of an international group of academic and biotechnological researchers. Topics range from early detection programs focusing on genetic factors, novel probes for detecting B-amyloid in the living brain, and the use of telephonic screening and MRI's to the diversity of therapeutic areas such as antioxidants, estrogen agonists and various anti-B-amyloid and anti-tangle approaches. The volume is still an indispensable resource for the psychogeriatrician, psychiatrist, clinical investigator, and neurobiologist, and a must for medical libraries. 410 0$aISOA Annual Investigators Meeting 606 $aAlzheimer's disease$xChemotherapy$vCongresses 606 $aAlzheimer's disease$xChemotherapy$xEvaluation$vCongresses 606 $aDrugs$xTesting$vCongresses 608 $aElectronic books. 615 0$aAlzheimer's disease$xChemotherapy 615 0$aAlzheimer's disease$xChemotherapy$xEvaluation 615 0$aDrugs$xTesting 676 $a616.8/31061 701 $aFillit$b Howard$01051375 701 $aO'Connell$b Alan W$01051376 712 02$aInstitute for the Study of Aging. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910454146903321 996 $aDrug discovery and development for Alzheimer's disease 2000$92481847 997 $aUNINA LEADER 01091nam a2200265 i 4500 001 991001494139707536 008 111121s1986 it b 00 0 ita d 020 $a8814009880 035 $ab14023428-39ule_inst 040 $aDip.to Studi Giuridici$bita 082 0 $a346.450323 100 1 $aGiannini, Gennaro$0227720 245 13$aIl danno alla persona come danno biologico :$bconfronto tra il metodo tradizionale di risarcimento e il nuovo metodo alternativo /$cGennaro Giannini 260 $aMilano :$bGiuffrè,$c1986 300 $a144 p. ;$c24 cm. 440 0$aCollana di studi (Centro studi assicurativi, Milano) ;$v9 504 $aContiene bibliografia 650 4$aDanni alla persona$xRisarcimento 650 4$aDanni alla persona$xValutazione 907 $a.b14023428$b02-04-14$c21-11-11 912 $a991001494139707536 945 $aLE027 346.03 GIA02.01$g1$i2027000292561$lle027$og$pE25.00$q-$rl$s- $t0$u3$v7$w3$x0$y.i15349287$z21-11-11 996 $aDanno alla persona come danno biologico$9243165 997 $aUNISALENTO 998 $ale027$b21-11-11$cm$da $e-$fita$git $h3$i0